AgeX Therapeutics, a subsidiary of BioTime, is focused on developing novel therapeutics for age-related degenerative diseases. The company has three product lines: iTR for cancer, AGEX-BAT1 for age-related metabolic disorders, and AGEX-VASC1 for cardiovascular regeneration. AgeX leverages intellectual property assets from its parent group and is currently conducting animal studies for its iTR technology. Additionally, the company is developing cell-based therapies and drug-based formulations to restore regenerative potential in aged tissues.